Business Wire Industry News

Friday, December 1, 2023

Ambio Announces US FDA Approval of a Generic Version of Forteo® (Teriparatide Injection) for Its Partner Apotex

BEECH ISLAND, S.C.--(BUSINESS WIRE)--Ambio, Inc., an innovative biotech company developing novel peptide drugs, biosimilar, bioequivalent, and other complex generic drugs, announced today that a generic version of Forteo®1 (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the U.S. Food and Drug Administration (FDA). “Ambio is a world leader in developing complex peptides. Our highly skilled techniques in controlling various kinds of peptide-r

Thursday, November 30, 2023

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas). For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the

Thursday, November 30, 2023

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”). “We are delighted to share tha

Wednesday, November 29, 2023

ZYUS Life Sciences Corporation Reports Q3 2023 Results

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced its 2023 Third Quarter Business results. During the third quarter of 2023, the Company completed an evaluation of the transactions relating to the Arrangement Agreement with Phoenix and the accounting treatment of tho

Wednesday, November 29, 2023

Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI (“Phenomic”) today announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines to transform the lives o

Wednesday, November 29, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatmen

Tuesday, November 28, 2023

Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update. "We recently achieved a significant milestone in our journey with the

Tuesday, November 28, 2023

TAP Network Releases 2023 Report on Diversity within Canada’s Tech Sector

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #tapnetwork--Tech and People Network (TAP Network) today announced the release of their 2023 Diversity in Tech Dashboard, which reports year-over-year progress on the representation of equity-deserving groups in Canada’s tech sector. While the report shows 2SLGBTQ and people of colour are well represented in the sector, women, Indigenous peoples and people with disabilities remain significantly underrepresented. In 2023, 189 Canadian technology companies partici

Tuesday, November 28, 2023

CASTL Opens Biomanufacturing Training Facility in Quebec

MONTREAL--(BUSINESS WIRE)--The Canadian Alliance for Skills and Training in Life Sciences (CASTL) unveiled its new biomanufacturing training facility in Montreal, Quebec yesterday afternoon. Located at the Angus Technopole in east Montreal, the new facility responds to the demand for highly skilled personnel in Quebec’s growing biomanufacturing sector by offering a wide range of technical bioprocessing training. "This is a major milestone in CASTL’s mission to enable the growth of the biomanufa

Monday, November 27, 2023

CASTL launches national biomanufacturing training program powered by Upskill Canada

CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--Today, the Canadian Alliance for Skills and Training in Life Sciences (CASTL) announces the launch of its national biomanufacturing skills and training program – CASTL Elevate. CASTL Elevate is powered by Upskill Canada, and is part of the first wave of partnership programs that are taking an industry-informed approach to supporting workers in Canada’s fast-growing biomanufacturing sector. Support from Upskill Canada will allow CASTL to trai

Monday, November 27, 2023

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director changes and upcoming financial reporting activities. New Board Chairman Mitch Levine joined the Board of Directors of IPA at IPA’s recent Annual General Meeting and has been appointed as Chairman of the Board, bringing a wealth of experience from the l

Monday, November 27, 2023

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal publ